glyburide has been researched along with Infant, Newborn, Diseases in 27 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Infant, Newborn, Diseases: Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The relationships between glyburide concentration and the time since the last intake of glyburide and between fetal glyburide concentration and neonatal hypoglycemia were modeled with linear or logistic regressions using fractional polynomials." | 9.34 | Transplacental transfer of glyburide in women with gestational diabetes and neonatal hypoglycemia risk. ( Alvarez, JC; Bouchghoul, H; Bouyer, J; Senat, MV; Verstuyft, C, 2020) |
| "Glyburide is thought to be safe for use during pregnancy for treatment of gestational diabetes mellitus (GDM)." | 7.81 | Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes. ( Benjamin, DK; Boggess, K; Brookhart, MA; Camelo Castillo, W; Jonsson Funk, M; Stürmer, T, 2015) |
| " The relationships between glyburide concentration and the time since the last intake of glyburide and between fetal glyburide concentration and neonatal hypoglycemia were modeled with linear or logistic regressions using fractional polynomials." | 5.34 | Transplacental transfer of glyburide in women with gestational diabetes and neonatal hypoglycemia risk. ( Alvarez, JC; Bouchghoul, H; Bouyer, J; Senat, MV; Verstuyft, C, 2020) |
| " Glyburide significantly increased the risk of any neonatal hypoglycemia [risk ratio (RR), 1." | 4.95 | Comparison of glyburide and insulin in the management of gestational diabetes: A meta-analysis. ( Chen, L; Chen, Y; Feng, W; Irwin, DM; Liu, Y; Si, X; Song, R, 2017) |
| "4%) had at least one episode of hypoglycemia, most often in the setting of glyburide." | 4.12 | Antenatal maternal hypoglycemia in women with gestational diabetes mellitus and neonatal outcomes. ( Cruz, M; Davitt, C; Harrison, RK; Palatnik, A; Saravanan, V, 2022) |
| "Glyburide is thought to be safe for use during pregnancy for treatment of gestational diabetes mellitus (GDM)." | 3.81 | Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes. ( Benjamin, DK; Boggess, K; Brookhart, MA; Camelo Castillo, W; Jonsson Funk, M; Stürmer, T, 2015) |
| " Median frequencies of hypoglycemia and hyperglycemia were less than 5% of routine blood glucose assays and were similar with both dosage forms." | 2.90 | Glibenclamide oral suspension: Suitable and effective in patients with neonatal diabetes. ( Baptiste, A; Beltrand, J; Berdugo, M; Bouazza, N; Boucheron, A; Busiah, K; Djerada, Z; Elie, C; Godot, C; Gozalo, C; Polak, M; Tréluyer, JM, 2019) |
| " The starting dosage for glyburide was 2." | 2.87 | Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial. ( Affres, H; Beucher, G; Bourcigaux, N; Bouyer, J; Bretelle, F; Castera, V; Cazaubiel, M; Coustols-Valat, M; De Carne, C; Deruelle, P; Desbriere, R; Héron, I; Jacquier, JF; Laboureau, S; Legardeur, H; Letourneau, A; Maillot, F; Mitanchez, D; Morin, M; Rod, A; Rolland, C; Sénat, MV; Sentilhes, L; Simon, E; Verspyck, E, 2018) |
| "Hypotonia was the symptom that responded best." | 2.82 | Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses. ( Beltrand, J; Berdugo, M; Bernardo, WM; de Gouveia Buff Passone, C; Garcin, L; Giani, E; Kariyawasam, D; Polak, M; Vaivre-Douret, L, 2022) |
| "A male infant patient developed diabetic ketoacidosis at 2 months-of-age due to the heterozygous ABCC8 gene mutation (p." | 1.56 | Neonatal diabetes caused by the heterozygous Pro1198Leu mutation in the ABCC8 gene in a male infant: 6-year clinical course. ( Akamizu, T; Ariyasu, H; Doi, A; Furuta, H; Furuta, M; Iwakura, H; Iwamoto, M; Matsuno, S; Matsutani, N; Miyawaki, M; Morita, S; Nishi, M; Shima, Y; Suzuki, H; Uraki, S, 2020) |
| " They exhibit marked sensitivity to sulfonylurea therapy with current dosing at 0." | 1.40 | Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy. ( Ham, JN; Heptulla, R; Hicks, KA; Kushner, JA, 2014) |
| "Neonates born to women with gestational diabetes managed on glyburide, and were more likely to be macrosomic and to be admitted to the intensive care unit compared to those treated with insulin injections." | 1.38 | Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes. ( Block-Kurbisch, I; Caughey, AB; Cheng, YW; Chung, JH; Inturrisi, M, 2012) |
| " On DOL 25, the glyburide dosage was decreased to 0." | 1.35 | An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus. ( Bremer, AA; Glaser, NS; Loomba-Albrecht, LA; Styne, DM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 17 (62.96) | 24.3611 |
| 2020's | 8 (29.63) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, DQ | 1 |
| Xu, GX | 1 |
| Teng, XY | 1 |
| Xu, JW | 1 |
| Tang, LF | 1 |
| Feng, C | 1 |
| Rao, JP | 1 |
| Jin, M | 1 |
| Wang, LQ | 1 |
| Harrison, RK | 1 |
| Saravanan, V | 1 |
| Davitt, C | 1 |
| Cruz, M | 1 |
| Palatnik, A | 1 |
| de Gouveia Buff Passone, C | 1 |
| Giani, E | 1 |
| Vaivre-Douret, L | 1 |
| Kariyawasam, D | 1 |
| Berdugo, M | 2 |
| Garcin, L | 1 |
| Beltrand, J | 2 |
| Bernardo, WM | 1 |
| Polak, M | 2 |
| Walton-Betancourth, S | 1 |
| Ashford, J | 1 |
| Beardsall, K | 1 |
| Gooding, N | 1 |
| Gurnell, EM | 1 |
| Hendriks, E | 1 |
| Hysted, H | 1 |
| Lee, J | 1 |
| Thankamony, A | 1 |
| Tseretopoulou, X | 1 |
| Win, M | 1 |
| Williams, RM | 1 |
| Yadav, A | 3 |
| Kumar, R | 3 |
| Rawat, A | 3 |
| Venkatesan, R | 3 |
| Mancioppi, V | 1 |
| Pozzi, E | 1 |
| Zanetta, S | 1 |
| Missineo, A | 1 |
| Savastio, S | 1 |
| Barbetti, F | 1 |
| Mellone, S | 1 |
| Giordano, M | 1 |
| Rabbone, I | 1 |
| Uraki, S | 1 |
| Furuta, H | 1 |
| Miyawaki, M | 1 |
| Matsutani, N | 1 |
| Shima, Y | 1 |
| Iwamoto, M | 1 |
| Matsuno, S | 1 |
| Morita, S | 1 |
| Furuta, M | 1 |
| Doi, A | 1 |
| Iwakura, H | 1 |
| Ariyasu, H | 1 |
| Nishi, M | 1 |
| Suzuki, H | 1 |
| Akamizu, T | 1 |
| Bouchghoul, H | 1 |
| Alvarez, JC | 1 |
| Verstuyft, C | 1 |
| Bouyer, J | 2 |
| Senat, MV | 2 |
| Kylat, RI | 1 |
| Senguttuvan, R | 1 |
| Bader, MY | 1 |
| Song, R | 1 |
| Chen, L | 1 |
| Chen, Y | 1 |
| Si, X | 1 |
| Liu, Y | 2 |
| Irwin, DM | 1 |
| Feng, W | 1 |
| Li, X | 1 |
| Xu, A | 1 |
| Sheng, H | 1 |
| Ting, TH | 1 |
| Mao, X | 1 |
| Huang, X | 1 |
| Jiang, M | 1 |
| Cheng, J | 1 |
| Liu, L | 1 |
| Neumann, U | 1 |
| Bührer, C | 1 |
| Blankenstein, O | 1 |
| Kühnen, P | 1 |
| Raile, K | 1 |
| Yildiz, M | 1 |
| Akcay, T | 1 |
| Aydin, B | 1 |
| Akgun, A | 1 |
| Dogan, BB | 1 |
| De Franco, E | 1 |
| Ellard, S | 2 |
| Onal, H | 1 |
| Affres, H | 1 |
| Letourneau, A | 1 |
| Coustols-Valat, M | 1 |
| Cazaubiel, M | 1 |
| Legardeur, H | 1 |
| Jacquier, JF | 1 |
| Bourcigaux, N | 1 |
| Simon, E | 1 |
| Rod, A | 1 |
| Héron, I | 1 |
| Castera, V | 1 |
| Sentilhes, L | 1 |
| Bretelle, F | 1 |
| Rolland, C | 1 |
| Morin, M | 1 |
| Deruelle, P | 1 |
| De Carne, C | 1 |
| Maillot, F | 1 |
| Beucher, G | 1 |
| Verspyck, E | 1 |
| Desbriere, R | 1 |
| Laboureau, S | 1 |
| Mitanchez, D | 1 |
| Ioacara, S | 1 |
| Sava, E | 1 |
| Barosan, A | 1 |
| Cojocaru, F | 1 |
| Gutan, A | 1 |
| Fica, S | 1 |
| Baptiste, A | 1 |
| Busiah, K | 1 |
| Bouazza, N | 1 |
| Godot, C | 1 |
| Boucheron, A | 1 |
| Djerada, Z | 1 |
| Gozalo, C | 1 |
| Tréluyer, JM | 1 |
| Elie, C | 1 |
| Yang, W | 1 |
| Wei, H | 1 |
| Sang, Y | 1 |
| Hicks, KA | 1 |
| Kushner, JA | 1 |
| Heptulla, R | 1 |
| Ham, JN | 1 |
| Verstappen, S | 1 |
| Mul, D | 1 |
| Prado-Carro, AM | 1 |
| Calzada-Hernández, J | 1 |
| Marín, S | 1 |
| Cardona-Hernandez, R | 1 |
| Oriola, J | 1 |
| Nicolás, M | 1 |
| Ramon-Krauel, M | 1 |
| Oka, H | 1 |
| Suzuki, S | 1 |
| Furuya, A | 1 |
| Matsuo, K | 1 |
| Amamiya, S | 1 |
| Oshima, M | 1 |
| Oka, T | 1 |
| Mukai, T | 1 |
| Okayama, A | 1 |
| Araki, A | 1 |
| Azuma, H | 1 |
| Tanahashi, Y | 1 |
| Camelo Castillo, W | 1 |
| Boggess, K | 1 |
| Stürmer, T | 1 |
| Brookhart, MA | 1 |
| Benjamin, DK | 1 |
| Jonsson Funk, M | 1 |
| Hashimoto, Y | 1 |
| Dateki, S | 1 |
| Hirose, M | 1 |
| Satomura, K | 1 |
| Sawada, H | 1 |
| Mizuno, H | 1 |
| Sugihara, S | 1 |
| Maruyama, K | 1 |
| Urakami, T | 1 |
| Sugawara, H | 1 |
| Shirai, K | 1 |
| Yorifuji, T | 1 |
| Loomba-Albrecht, LA | 1 |
| Glaser, NS | 1 |
| Styne, DM | 1 |
| Bremer, AA | 1 |
| Cheng, YW | 1 |
| Chung, JH | 1 |
| Block-Kurbisch, I | 1 |
| Inturrisi, M | 1 |
| Caughey, AB | 1 |
| Siklar, Z | 1 |
| Okulu, E | 1 |
| Berberoğlu, M | 1 |
| Young, E | 1 |
| Savaş Erdeve, S | 1 |
| Mungan, IA | 1 |
| Hacihamdioğlu, B | 1 |
| Erdeve, O | 1 |
| Arsan, S | 1 |
| Oçal, G | 1 |
| Omori, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes[NCT01731431] | Phase 3 | 914 participants (Actual) | Interventional | 2012-05-18 | Completed | ||
| Tolerance and Acceptability of Glibentek in Patients With Neonatale Diabetes Secondary to Mutations in K+-ATP Channels[NCT02375828] | Phase 3 | 10 participants (Actual) | Interventional | 2015-03-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for glyburide and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Glycemic control and neonatal outcomes in women with gestational diabetes mellitus treated using glyburide, metformin, or insulin: a pairwise and network meta-analysis.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Glycemic Control; Humans; Hypoglycem | 2021 |
Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses.
Topics: Adult; Child; Diabetes Mellitus; Epilepsy; Glyburide; Humans; Infant, Newborn; Infant, Newborn, Dise | 2022 |
Comparison of glyburide and insulin in the management of gestational diabetes: A meta-analysis.
Topics: Adult; Birth Weight; Diabetes, Gestational; Disease Management; Female; Glyburide; Humans; Hypoglyce | 2017 |
[Medical management of pregnant women with diabetes].
Topics: Blood Glucose; Body Weight; Congenital Abnormalities; Diabetic Nephropathies; Diabetic Retinopathy; | 2002 |
3 trials available for glyburide and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Transplacental transfer of glyburide in women with gestational diabetes and neonatal hypoglycemia risk.
Topics: Administration, Oral; Adult; Diabetes, Gestational; Dose-Response Relationship, Drug; Female; Fetal | 2020 |
Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial.
Topics: Administration, Oral; Adult; Blood Glucose; Diabetes, Gestational; Female; Fetal Macrosomia; Glyburi | 2018 |
Glibenclamide oral suspension: Suitable and effective in patients with neonatal diabetes.
Topics: Administration, Oral; Adolescent; Blood Glucose; Child; Child, Preschool; Diabetes Mellitus; Female; | 2019 |
20 other studies available for glyburide and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Antenatal maternal hypoglycemia in women with gestational diabetes mellitus and neonatal outcomes.
Topics: Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agent | 2022 |
Early Postnatal Use of Glibenclamide in Permanent Neonatal Diabetes Secondary to Antenatally Diagnosed KJCN11 Mutation.
Topics: Blood Glucose; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Agents; Infant; Infant, Ne | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Age | 2023 |
Neonatal diabetes caused by the heterozygous Pro1198Leu mutation in the ABCC8 gene in a male infant: 6-year clinical course.
Topics: Diabetic Ketoacidosis; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infant, Newborn; | 2020 |
Personalized precision medicine in extreme preterm infants with transient neonatal diabetes mellitus.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Female; Genetic Testing; Glyburide; High-Throughput Nucleot | 2017 |
Early transition from insulin to sulfonylureas in neonatal diabetes and follow-up: Experience from China.
Topics: China; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 1; Cohort Studies; Diabet | 2018 |
Primary sulphonylurea therapy in a newborn with transient neonatal diabetes attributable to a paternal uniparental disomy 6q24 (UPD6).
Topics: Administration, Oral; Berlin; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Dr | 2018 |
Emergence of insulin resistance following empirical glibenclamide therapy: a case report of neonatal diabetes with a recessive INS gene mutation.
Topics: Blood Glucose; Consanguinity; Diabetes Mellitus; Glyburide; Homozygote; Humans; Infant, Newborn; Inf | 2018 |
To diet or not to diet in neonatal diabetes responding to sulfonylurea treatment.
Topics: Combined Modality Therapy; Diabetes Mellitus; Diet, Carbohydrate-Restricted; Female; Glyburide; Huma | 2018 |
KCNJ11 in-frame 15-bp deletion leading to glibenclamide- responsive neonatal diabetes mellitus in a Chinese child.
Topics: Asian People; Diabetes Mellitus; DNA Mutational Analysis; Female; Gene Deletion; Glyburide; Humans; | 2013 |
Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy.
Topics: Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Glyburide; Humans; Hypoglycemic Agents; | 2014 |
A 'picturesque' case of transition from subcutaneous to oral treatment in neonatal diabetes.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genetic Testing; Glyburide; | 2014 |
Patient with iDEND syndrome-related mutation.
Topics: Diabetes Mellitus; Epilepsy; Female; Glyburide; Humans; Hypoglycemic Agents; Infant, Newborn; Infant | 2014 |
Glycemic control and motor development in a patient with intermediate DEND.
Topics: Child Development; Diabetes Mellitus; Epilepsy; Glucose; Glyburide; Humans; Infant; Infant, Newborn, | 2014 |
Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes.
Topics: Adult; Cohort Studies; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Infant | 2015 |
Molecular and clinical features of K
Topics: Amino Acid Substitution; Congenital Hyperinsulinism; Diabetes Mellitus; DNA Mutational Analysis; Dru | 2017 |
An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Glyburide; | 2009 |
Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes.
Topics: Adolescent; Adult; Cohort Studies; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Ag | 2012 |
Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant.
Topics: Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Infant; Infant, Newborn; Infant, Newborn, | 2011 |